公开(公告)号：US20170165262A1

公开(公告)日：2017-06-15

申请号：US15436037

申请日：2017-02-17

Applicant: FUJIFILM Corporation

Inventor： Tomoki NAOE ,  Hitoshi KIYOI ,  Shinji HAGIWARA ,  Masaru TAKASAKI ,  Daisuke HIRANO ,  Toshiyuki NAKATANI ,  Takeshi YAMAURA

IPC: A61K31/506 ,  A61K31/505 ,  A61K31/5377

CPC classification number: A61K31/506 ,  A61K31/505 ,  A61K31/5377 ,  C12N9/12 ,  C12N9/1205 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.

公开(公告)号：US20150045339A1

公开(公告)日：2015-02-12

申请号：US14516337

申请日：2014-10-16

Applicant: FUJIFILM Corporation

Inventor： Masaru TAKASAKI ,  Toshiaki TSUJINO ,  Shintarou TANABE ,  Megumi OOKUBO ,  Kimihiko SATO ,  Atsushi HIRAI ,  Daisuke TERADA ,  Shinsuke INUKI ,  Shinsuke MIZUMOTO

IPC: C07D471/04 ,  C07D401/14 ,  C07D239/48 ,  C07D403/12 ,  C07D413/04 ,  C07D403/14 ,  C07D413/14 ,  C07D405/12 ,  C07D401/06 ,  C07D403/04 ,  C07D417/12 ,  C07D409/12 ,  C07D401/12 ,  C07D413/12

CPC classification number: C07D471/04 ,  A61K31/44 ,  A61K31/505 ,  C07D213/74 ,  C07D239/48 ,  C07D239/49 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The object is to provide an Fms-like tyrosine kinase 3 (FLT3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (AML). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided. The compound or a salt thereof of the present invention can be used as an active ingredient of a pharmaceutical composition for a treatment of a disease or condition relating to FLT3, such as acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).

Abstract translation: 目的是提供可用作急性骨髓性白血病（AML）治疗剂的Fms样酪氨酸激酶3（FLT3）抑制剂。 提供了由通式[1]表示的新型含氮杂环化合物或其盐。 本发明的化合物或其盐可以用作治疗与FLT3有关的疾病或病症的药物组合物的活性成分，例如急性骨髓性白血病（AML）和急性早幼粒细胞白血病（APL）。